Acurx Pharmaceuticals, Inc. (ACXP)
ACXP moved a median of -0.52% 30 minutes after news, and -1.55% by the close. How ACXP actually reacts to news — the realized, point-in-time move the market made, measured across 233 labeled events over the last three years with zero look-ahead.
ACXP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 225 |
| 30-min | -0.52% | 37% | 231 |
| 60-min | -0.69% | 36% | 232 |
| to close | -1.55% | 37% | 230 |
| Middle 50% of ACXP reactions | -3.27% to +1.19% |
|---|---|
| Median reaction (30-min) | -0.52% |
| Measured reactions | 233 |
Half of all Acurx Pharmaceuticals, Inc. news events land between -3.27% and +1.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ACXP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACXP's baseline. Nothing else.
Recent ACXP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Acurx Pharmaceuticals, For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street | Press release | ACCESS Newswire | +0.75% | -2.24% | |
| Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection | Press release | PR Newswire | -2.17% | -5.43% | |
| Form EFFECT Acurx Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +2.21% | |
| Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and | Press release | PR Newswire | +0.71% | -0.71% | |
| Form S-1 Acurx Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | — | -1.40% | |
| Form ARS Acurx Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.42% | |
| Form DEF 14A Acurx Pharmaceuticals, For: Oct 16 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.42% | |
| Form DEFA14A Acurx Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.42% | |
| Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat | Press release | PR Newswire | +0.00% | +17.86% | |
| Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update | Press release | PR Newswire | -2.79% | -0.36% | |
| Form 10-Q Acurx Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.79% | -0.36% | |
| Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics | Press release | PR Newswire | -0.97% | +0.00% | |
| Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics | Press release | PR Newswire | -0.65% | — | |
| FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurre | Press release | PR Newswire | +1.38% | -1.38% | |
| Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection | Press release | PR Newswire | +0.00% | +3.13% | |
| Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update | Press release | PR Newswire | +0.69% | -6.21% | |
| Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference | Press release | PR Newswire | +0.00% | -4.94% | |
| Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat | Press release | ACCESS Newswire | +1.12% | +5.62% | |
| Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update | Press release | PR Newswire | -3.21% | -5.96% | |
| Form EFFECT Acurx Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -3.21% | -5.96% | |
| Form 10-Q Acurx Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.21% | -5.96% | |
| Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 | Press release | PR Newswire | +0.46% | -3.18% | |
| Form S-1 Acurx Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +0.96% | -4.31% | |
| Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase | Press release | PR Newswire | +1.94% | -4.37% | |
| Form D Acurx Pharmaceuticals, | SEC filing · Form D | SEC EDGAR | +2.56% | +10.77% | |
| Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update | Press release | PR Newswire | +1.33% | +3.96% | |
| Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | +0.19% | -8.11% | |
| Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -10.93% | -1.58% | |
| Form 8-K Acurx Pharmaceuticals, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -10.93% | -1.58% | |
| New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events | Press release | ACCESS Newswire | +1.31% | +0.33% | |
| New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST) | Press release | ACCESS Newswire | +0.27% | -3.01% | |
| Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors | Press release | PR Newswire | +14.66% | -8.38% | |
| Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update | Press release | PR Newswire | -1.65% | -8.71% | |
| Form 10-K Acurx Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.65% | -8.71% | |
| Form S-8 Acurx Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -1.65% | -8.71% | |
| Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection | Press release | PR Newswire | +3.21% | +39.64% | |
| Form 8-K Acurx Pharmaceuticals, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +3.21% | +39.64% | |
| Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update | Press release | PR Newswire | -1.01% | +0.51% | |
| Form EFFECT Acurx Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -0.49% | -5.94% | |
| Form S-1 Acurx Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | -1.25% | -5.39% | |
| USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors | Press release | PR Newswire | +3.73% | -1.25% | |
| Form EFFECT Acurx Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.15% | -2.02% | |
| Form S-3/A Acurx Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | -0.66% | -4.60% | |
| Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals | Press release | PR Newswire | +0.00% | +2.84% | |
| Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update | Press release | PR Newswire | +3.99% | -5.32% | |
| Form 10-Q Acurx Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.99% | -5.32% | |
| Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens | Press release | PR Newswire | -1.79% | +7.58% | |
| Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference | Press release | PR Newswire | -0.08% | -4.11% | |
| Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update | Press release | PR Newswire | +0.16% | +4.43% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACXP section they belong to.
Where else ACXP is measured.
ACXP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Acurx Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ACXP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 233 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of ACXP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ACXP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.